Showing 5071-5080 of 5621 results for "".
- Study: Eye Damage Linked to Over-the-Counter Vitamin That Lowers Cholesterol Can Be Reversedhttps://modernod.com/news/study-eye-damage-linked-to-over-the-counter-vitamin-that-lowers-cholesterol-can-be-reversed/2477051/In a first-of-its-kind clinical report, retina specialists at the New York Eye and Ear Infirmary of Mount Sinai (NYEE) have shown that severe vision loss from a self-prescribed high dose of over-the-counter niacin is linked to injury of a specific cell type in a patient’s eye. The experts report
- NovaBay Pharmaceuticals to Distribute the NuLids System for the Treatment of Dry Eye in Certain U.S. Geographieshttps://modernod.com/news/novabay-pharmaceuticals-to-distribute-the-nulids-system-for-the-treatment-of-dry-eye-in-certain-u-s-geographies/2477048/NovaBay Pharmaceuticals announced an exclusive 90-day agreement with NuSight Medical to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accum
- Iveric bio’s Zimura Meets its Primary Endpoint in a Phase 2b Trial in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bios-zimura-meets-its-primary-endpoint-in-a-phase-2b-trial-in-geographic-atrophy-secondary-to-dry-amd/2477046/Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a random
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held
- Oculus Teams Up With BHVI to Improve Myopia Managementhttps://modernod.com/news/oculus-teams-up-with-bhvi-to-improve-myopia-management/2477036/Oculus and BHVI (Brien Holden Vision Institute) have announced an agreement that will allow Oculus to incorporate BHVI’s algorithms for tracking and estimating refractive error into its Myopia Master ophthalmic instruments developed for the management of myopia.
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Julia A. Haller, MD, Elected to National Academy of Medicinehttps://modernod.com/news/julia-a-haller-md-elected-to-national-academy-of-medicine/2477033/Wills Eye Hospital announced its Ophthalmologist-in-Chief, Julia A. Haller, MD, has been elected to the National Academy of Medicine (NAM), considered one of the highest honors in the fields of health and medicine, recognizing individuals who have demonstrated outstanding professional achievement
- Johnson & Johnson Vision Releases Data From Study of Acuvue Oasys With Transitions Light Intelligent Technologyhttps://modernod.com/news/johnson-johnson-vision-releases-data-from-study-of-acuvue-oasys-with-transitions-light-intelligent-technology/2477034/Johnson & Johnson Vision announced new data from a study of its Acuvue Oasys with Transitions Light Intelligent Technology, which found the benefits of these first-of-its-kind light adaptive contact lens were deemed highly valued and useful by people who had never w
- Bausch Health Licenses Clearside Biomedical’s Xipere, An Investigational Treatment For Macular Edema Associated With Uveitishttps://modernod.com/news/bausch-health-licenses-clearside-biomedicals-xipere-an-investigational-treatment-for-macular-edema-associated-with-uveitis/2477035/Bausch Health Companies announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the United States and